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OBJECTIVE — We studied differences between patients with latent autoimmune diabetes in
adults (LADA), type 2 diabetes, and classical type 1 diabetes diagnosed after age 35 years.
RESEARCH DESIGN AND METHODS — Polymorphisms in HLA-DQB1, INS, PTPN22,
andCTLA4weregenotypedinpatientswithLADA(n213),type1diabetesdiagnosedat35years
of age (T1D35y; n  257) or 20 years of age (T1D20y; n  158), and type 2 diabetes.
RESULTS — Although patients with LADA had an increased frequency of HLA-DQB1 and
PTPN22 risk genotypes and alleles compared with type 2 diabetic subjects, the frequency was
signiﬁcantlylowercomparedwithT1D35ypatients.Genotypefrequencies,measuresofinsulin
secretion, and metabolic traits within LADA differed according to GAD antibody (GADA) quar-
tiles, but even the highest quartile differed from type 1 diabetes. Having two or more risk
genotypes was associated with lower C-peptide concentrations in LADA.
CONCLUSIONS — LADA patients differed genetically and phenotypically from both
T1D35y and type 2 diabetic patients in a manner dependent on GADA levels.
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P
atients with latent autoimmune dia-
betes in adults (LADA) have a pro-
gressive insulin secretion defect,
havelessevidenceofmetabolicsyndrome
than type 2 patients, and share a genetic
predisposition with both type 1 and type
2 diabetic patients (1–5). Whether LADA
merely represents older-onset type 1 dia-
betes or is a distinct subgroup has been
debated(6),butstudiescomparingLADA
withclassicaltype1diabetesinacompar-
ative age-range are lacking. We investi-
gated 1) whether LADA differed
genetically (with respect to genes associ-
ated with risk of type 1 diabetes: HLA-
DQB1, PTPN22, INS, and CTLA4) and
phenotypically (with respect to metabolic
syndrome) from type 1 diabetes diag-
nosed after age 35 years; and 2) whether
theobservedclinicalheterogeneitywithin
LADA depended on GAD antibody
(GADA) levels and type 1 diabetes sus-
ceptibility genotypes.
RESEARCH DESIGN AND
METHODS— We included patients
with age at onset 35 years with LADA
(deﬁned here as GADA-positive diabetes
without insulin treatment for the ﬁrst 6
months; n  213) or with type 1 diabe-
tes (T1D35y; n  35), patients with
type 1 diabetes diagnosed at 20 years
of age (T1D20y; n  158), and GADA-
positive type 2 diabetic patients (n 
648) from the Botnia study (2) together
with T1D35y patients (n  222) from
the FinnDiane study (7). The non–
insulin-treated subjects underwent an
oral glucose tolerance test with blood
samples drawn at 5, 0, 30, 60, and
120 min for measurement of plasma
glucose, serum insulin, C-peptide, lip-
ids, and GADA levels (8). The HLA-
DQB1*02, *0301, *0302, *0602, and
*0603 alleles were genotyped (9) and
classiﬁed as risk (*0302/*02, 0302/X),
protective [*0602(3)/X, *0602(3)/
*0301], or neutral (all other) (X  ho-
mozygous or other allele). The INS 
Hph23 A/T (rs689), CTLA4 CT60
(rs3087243), and PTPN22 1858CT
(rs2476601) variants were genotyped
with TaqMan allelic discrimination (Ap-
plied Biosystems, Foster City, CA). Statis-
tical analyses were performed with
Statistical Package for Social Science soft-
ware(version13.0;SPSS,Chicago,IL)us-
ing the 
2 test, the Kruskal-Wallis test, or
a general linear model. Participants gave
informed consent, and the study was ap-
proved by the local ethics committee.
RESULTS— The HLA-DQB1 risk ge-
notypes were most frequent in T1D20y
patients (75.3%), followed by T1D35y
patients (50.2%) and LADA patients
(32.2%) (P  0.00001; Fig. 1), with the
opposite trend for the protective geno-
types. The type 1 diabetic patients also
hadahigherfrequencyofthePTPN22risk
allele (T1D20y 17.7% and T1D35y
21.1%) than LADA patients (14.5%; P 
0.008). Compared with type 2 diabetes,
the HLA-DQB1 (P  0.00001) and
PTPN22 risk genotypes and alleles (P 
0.04–0.008) were signiﬁcantly more
common in LADA. The INS and CTLA4
risk genotypes were only associated with
type 1 diabetes (T1D35y, LADA, type 2
diabetes: INS 77.4, 58.7, and 56.5%, re-
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41.6%, respectively).
All risk genotypes and alleles were
most prevalent in patients in the highest
GADA quartile (LADAhigh, GADA 278
IU/ml) compared with the two middle
(LADAmid, 44–278 IU/ml) or the lowest
quartiles (LADAlow, 33–43.9 IU/ml; Fig.
1), but the difference was signiﬁcant only
for HLA-DQB1 (P  0.009). However,
even LADAhigh subjects differed from
T1D35y subjects (P  0.001), and
LADAlow subjects had nonsigniﬁcantly
moreHLA-DQB1riskgenotypesthantype
2 diabetic subjects (19.6 vs. 14.0%).
LADAhigh subjects also differed from the
type 2 diabetic subjects with respect
to the allele frequency of PTPN22 (P 
0.02) and CTLA4 (P  0.03).
In a joint analysis of the four genes,
two or more risk genotypes were most
common in T1D20y patients (82.1%),
followed by T1D35y patients (74.4%),
LADA (54.1%), and type 2 diabetic
(38.7%) patients (P  0.00001). The fre-
quency differed across the GADA quar-
tiles (P  0.004), and it was similar in
LADAhigh and T1D35y patients (72.5 vs.
74.4%), as well as in LADAlow and type 2
diabetic patients (46.0 vs. 38.7%) (online
appendix Table A3, available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-2188/DC1). LADA patients with an
increasing number of risk genotypes had
decreasing fasting serum (fS)–C-peptide
concentrations (P  0.015).
The LADA patients had higher BMI
and lipid concentrations than the
T1D35y patients (online appendix Table
A1). Compared with type 2 diabetic pa-
tients, LADA patients had lower insulin
secretion and BMI, as well as a better
lipid proﬁle. Going from LADAlow to
LADAhigh,therewasasigniﬁcanttrendto-
ward lower insulin secretion, lipid levels,
and BMI (online appendix Table A2).
However,thefS–C-peptideconcentration
was higher in LADAhigh patients com-
pared with T1D35y patients and was
somewhat lower in LADAlow compared
with type 2 diabetic patients. Despite the
marked age difference, the T1D35y and
T1D20y patients were metabolically
similar.
CONCLUSIONS — We have shown
a signiﬁcant genetic difference between
LADAandtype1diabetesdiagnosedafter
age 35 years. Although HLA-DQB1 and
PTPN22 risk genotypes were increased in
LADA,theyweremuchlesscommonthan
in type 1 diabetes. INS and CTLA4 were
only associated with type 1 diabetes.
As suggested previously (3,5,10), ge-
netic differences and clinical phenotype
were associated with GADA levels, ex-
plaining some of the observed heteroge-
neitywithinLADA.Ofnote,theLADAhigh
group (GADA 278 IU/ml) roughly cor-
responds to the high GADA group (300
IU/ml) in the Non Insulin Requiring Au-
toimmune Diabetes (NIRAD) Study, in
which association with PTPN22 was also
found only in patients with high GADA
(10).
Our study is the largest to date in
adult-onset type 1 diabetic patients. In
agreement with a smaller study (11), we
clearly showed a lower frequency of
DQB1 risk genotypes in T1D35y com-
pared with T1D20y patients. However,
protective HLA-DQB1 genotypes were as
Figure 1—On the left, distribution of HLA-DQB1 genotypes and PTPN22 (rs2476601) alleles in type 1 diabetic patients (T1D20y, n  158) or
after the age of 35 years (T1D35y, n  257), LADA patients (n  213), and type 2 diabetic patients (T2D, n  648). On the right, distribution of
HLA-DQB1 genotypes and PTPN22 (rs2476601) alleles in LADA patients stratiﬁed according to GADA quartiles: the highest, LADAhigh (n  52);
the two middle quartiles pooled, LADAmid (n  109); and the lowest, LADAlow (n  52). Black columns represent risk genotypes and alleles, and
white columns represent protective (HLA-DQB1) or nonrisk (PTPN22) genotypes and alleles. The 
2 test was applied to test differences between
diabeticgroups.Signiﬁcantdifferencesareindicatedwithasterisks.*P0.05.**P0.0001.HLA-DQB1:P0.01acrosstheGADAquartilesofLADA.
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The prevalence of INS, PTPN22, and
CTLA4 risk genotypes was similar in the
two groups. As expected (2,4,10,12–14),
LADA had an increased frequency of
HLA-DQB1andPTPN22riskgenotypesas
well as a decreased frequency of HLA-
DQB1 protective genotypes compared
with type 2 diabetic subjects. Contrary to
previous reports (4,14,15), the INS vari-
ant was not associated with LADA in the
Finnish subjects.
In conclusion, we have shown that
patients with LADA differ genetically and
phenotypically from type 1 diabetic pa-
tients diagnosed after age 35 years. The
LADA group was heterogeneous, and
both the genotype distribution and phe-
notypic characteristics were associated
with GADA level. A signiﬁcant trend was
observed toward lower insulin secretion
and metabolic trait values going from the
lowest GADA quartile to the highest.
Thus, LADA patients with high GADA
concentrationsweremoresimilar,butnot
identical, to type 1 diabetic patients, and
those with low GADA concentrations
were more similar to type 2 diabetic
patients.
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